Invention Grant
- Patent Title: Inhibitors of aspartyl protease
-
Application No.: US12370175Application Date: 2009-02-12
-
Publication No.: US08455497B2Publication Date: 2013-06-04
- Inventor: Michael R. Hale , Roger Tung , Stephen Price , Robin David Wilkes , Wayne Carl Schairer , Ashley Nicholas Jarvis , Andrew Spaltenstein , Eric Steven Furfine , Vicente Samano , Istvan Kaldor , John Franklin Miller , Michael Stephen Brieger , Ronald George Sherrill
- Applicant: Michael R. Hale , Roger Tung , Stephen Price , Robin David Wilkes , Wayne Carl Schairer , Ashley Nicholas Jarvis , Andrew Spaltenstein , Eric Steven Furfine , Vicente Samano , Istvan Kaldor , John Franklin Miller , Michael Stephen Brieger , Ronald George Sherrill
- Applicant Address: US MA Cambridge
- Assignee: Vertex Pharmaceuticals Incorporated
- Current Assignee: Vertex Pharmaceuticals Incorporated
- Current Assignee Address: US MA Cambridge
- Agency: Ropes & Gray LLP
- Agent James F. Haley, Jr.; Karen Mangasarian
- Main IPC: C07D493/04
- IPC: C07D493/04 ; A61K31/34 ; A61K31/357 ; A61K31/36 ; A61P31/18 ; C07C311/16 ; C07C311/29
Abstract:
The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
Public/Granted literature
- US20090274650A1 INHIBITORS OF ASPARTYL PROTEASE Public/Granted day:2009-11-05
Information query
